ILIngrid López-Reyna

Ingrid López-Reyna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ingrid López-Reyna has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • High-Dose methotrexate in pediatric acute lymphoblastic leukemia: Variability across Mexican centers from a national survey

    by Julia E Colunga-Pedraza, Oscar González-Ramella, Pablo González-Montalvo, Daniela Arce Cabrera, Y Valentine Jiménez Antolinez, Ingrid López-Reyna, Daniel E Martínez-Martínez, Perla R Colunga-Pedraza, Lourdes Ríos-Farfán, Óscar González-Llano

    Introduction: High-dose methotrexate (HD-MTX) is a cornerstone of pediatric acute lymphoblastic leukemia (ALL) therapy. It's safe administration requires timely pharmacokinetic monitoring and comprehensive supportive care, which are frequently limited in low- and middle-income countries (LMICs). In Mexico, variability in HD-MTX practices may compromise treatment safety and efficacy. This study aimed to characterize national practice patterns and identify context-specific adaptations in the delivery of HD-MTX in resource constrained settings. Methods: A nationwide, cross-sectional electronic survey was conducted between May and November 2023 among pediatric hematologists and oncologists treating patients younger than 18 years with ALL. The questionnaire assessed institutional guidelines, availability of pharmacokinetic monitoring, and supportive care practices, including hydration, urinary alkalinization, and folinic acid rescue. Data were analyzed descriptively. Results: A total of 111 specialists from 27 Mexican states participated. Only 56% reported having institutional HD-MTX guidelines. While 97% administered HD-MTX to high-risk ALL patients, only 61% used full protocol-recommended doses, and nearly one-third reported dose reductions. Methotrexate plasma level monitoring was only available in 56% of centers. Most centers (86%) administered HD-MTX exclusively in the inpatient setting. Supportive care practices varied substantially across institutions and risk groups. Reported barriers included limited laboratory capacity (61%), lack of standardized protocols (44%), and delays related to bed availability (39%). Conclusions: Optimizing HD-MTX delivery in Mexico requires integrating standardized clinical practices with targeted system-level interventions to ensure timely access to pharmacokinetic monitoring. The development and implementation of context-adapted national guidelines may improve safety, reduce variability in care, and mitigate outcome disparities in children with ALL.

  • Optimizing Blinatumomab Access for Low- and Middle-Income Countries: Feasibility of a Shortened, Vial-Sharing, Outpatient Approach for Pediatric ALL

    by Julia Esther Colunga Pedraza, Andrés Gómez-De León, Perla Rocío Colunga Pedraza, Ingrid Gabriela López Reyna, Claudia Gabriela Martínez Martínez, Yahaira Valentina Jiménez Antolinez, José Carlos Jaime-Pérez, David Gómez Almaguer, Óscar González Llano

    PURPOSE: This study aims to evaluate the safety, feasibility, effectiveness, and cost-saving potential of a shortened, vial-sharing outpatient blinatumomab regimen for treating relapsed or refractory (R/R) ALL in children. MATERIALS AND METHODS: We conducted a retrospective study of pediatric patients with R/R B-cell ALL (B-ALL) treated with a shortened outpatient blinatumomab regimen (<21 days), aiming to achieve a negative measurable residual disease (MRD) remission before hematopoietic stem-cell transplantation (HSCT). RESULTS: Twelve patients were included: three (25%) with primary refractory disease and nine (75%) with relapse. The median follow-up time was 33 months (range, 10-76 months). Blinatumomab was administered for a median of 19 days (range, 11-21), with 75% (9 of 12) of patients completing treatment entirely on an outpatient basis. Five patients (62%) achieved CR with undetectable MRD, and all four patients who initiated treatment because of persistent MRD achieved MRD clearance (100%). Ten patients (83%) proceeded to haploidentical HSCT. The estimated 3-year overall survival (OS) was 54%, and the relapse-free survival (RFS) was 44%. These optimization measures resulted in a 43% reduction in drug-related expenditures. CONCLUSION: Reduced-duration outpatient blinatumomab shows promise as a context-adapted strategy for heavily pretreated pediatric patients with ALL. Given the small retrospective cohort, these findings should be interpreted with caution.


  • Open Access

    Situational panorama of chronic liver diseases: A single-center experience at a university hospital in northeast Mexico (1995–2019)

    by Paula Cordero-Perez, Liliana Torres-González, Samuel Rivas-López, Carolina Treviño-García, Airam Regalado-Ceballos, Jaime R. Zúñiga-Noriega, Ingrid G. López-Reyna, Luz M. Barbosa-Castillo, Isai E. Hernández-Padilla, Linda E. Muñoz-Espinosa

  • Open Access

    Overcoming challenges to reduce time to antibiotic therapy in febrile neutropenic children: insights from a Mexican center

    by Julia Esther Colunga-Pedraza, Ingrid Gabriela Lopez-Reyna, Denisse Natalie Vaquera-Aparicio, Samantha Paulina Peña-Lozano, Jafet Arrieta, Lucía Elizabeth Hernández-Torres, Perla Rocío Colunga-Pedraza, Mónica Regalado, Yajaira Valentine Jiménez-Antolinez, Fernando García-Rodríguez, et al.


  • Open Access

    CRLF2 Expression in Mexicans with Acute Lymphoblastic Leukemia across the Age Spectrum

    by Héctor A. Martínez-Espinosa, Nereida Méndez-Ramírez, Julia Colunga Pedraza, Eli Fuentes-Chávez, Rosario Salazar-Riojas, Odra L. Martínez-González, Antonio Vega-Mateos, Oscar Gonzalez Llano, Ingrid López-Reyna, David Gomez-Almaguer, et al.

    Disclosures. Gomez-Almaguer:Novartis: Honoraria; Janssen: Consultancy, Honoraria; AMGEN: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria. Gomez-De Leon:A


  • Open Access

    Exploring the Efficacy and Feasibility of Outpatient Blinatumomab Short Cycles in Pediatric Patients with Relapsed/Refractory B-ALL in LMIC: Preliminary Results

    by Julia Esther Colunga Pedraza, Samantha Rodriguez, Ingrid López-Reyna, Lucía Hernández Torres, Perla Rocio Colunga Pedraza, Valeria Fuentes, David Gomez-Almaguer, Yajaira Valentina Jimenez-Antolinez, Oscar Gonzalez Llano

    Disclosures. Gomez-Almaguer:AMGEN: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Honoraria; AbbVie: Consultancy, Honoraria.Figure 1